The University of Kansas Health System is treating a total of 18 COVID patients today, 11 Friday. Other significant numbers:
- 7 with the active virus today, 5 Friday
- 0 in ICU, 0 Friday
- 0 on a ventilator, 0 Friday
Key points from today’s guests:
Dr. Sarah Hon, vice president of neurosciences, The University of Kansas Health System
- Migraine is not just a headache, it’s a disease that is often under recognized, but is common as it affects 1 in 10 Americans.
- About 18 percent of women have migraines, which include moderate to severe headaches, sensitivity to light and sound, and nausea.
- The wonderful thing about this drug and what's unique about it, is that it actually bypasses the GI system. Since many patients have nausea and even vomiting with migraine, this allows us to bypass that.
- These trials are extremely important because each patient has different needs and different treatment options can be beneficial.
Dr. Deetra Ford, division chief of general neurology, The University of Kansas Health System
- Chronic migraine is 15 migraines per month or more. Episodic migraine is only a few per month.
- This, along with other factors, are important in determining what types of treatments to use for migraine.
- Non-injection options are extremely important, especially for patients who do not do well with needles.
- Treating onset of headaches early can be important to overall health. Talk with your doctor if you are having regular headaches so it can be evaluated.
Dr. Charlie Conway, discovered & developed two gepant migraine treatments
- The FDA approved a new nasal spray in March for migraines that will be available later this summer.
- It blocks CGRP receptors in the brain and provides pain relief in 15 minutes for up to 48 hours.
- This part of a new class of drugs called gepants. It’s like putting tape over a keyhole, because it blocks the receptors.
- Most people with migraine symptoms have trouble functioning normally.
- This is the first ever of the class of gepants to be a nasal spray.
Dr. Dana Hawkinson, director of infection prevention & control, The University of Kansas Health System
- A new RSV vaccine will be coming this fall. The CDC Advisory Committee backs the vaccine.
- Talk with your doctor before getting the RSV vaccine.
- The vaccine helps protect against lower respiratory disease.
Wednesday, June 28 at 8 a.m. is the next Open Mics with Dr. Stites. How do doctors, pharmacists and patients navigate global drug shortages?
ATTENTION MEDIA: Please note access is with Microsoft Teams:
Join on your computer or mobile app
Click here to join the meeting
Meeting ID: 235 659 792 451
Passcode: 6CSfGE
Download Teams | Join on the web
Or call in (audio only)
+1 913-318-8863,566341546# United States, Kansas City
TVU Grid link: UoK_Health_SDI
Restream links: Facebook.com/kuhospital
YouTube.com/kuhospital
Send advance questions to medicalnewsnetwork@kumc.edu.